Source Profiling of Biohazardous Aerosols in Hospitals

This study has been completed.
Sponsor:
Collaborator:
Hong Kong University of Science and Technology
Information provided by:
Hospital Authority, Hong Kong
ClinicalTrials.gov Identifier:
NCT00517660
First received: August 15, 2007
Last updated: August 21, 2013
Last verified: August 2013
  Purpose

To characterise the physical parameters (number concentration, size distribution and their trajectories) of aerosols (droplets) generated in high risk procedures.


Condition
Respiratory Tract Infections

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Source Profiling of Biohazardous Aerosols in Hospitals

Further study details as provided by Hospital Authority, Hong Kong:

Enrollment: 60
Study Start Date: March 2006
Study Completion Date: June 2006
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Sampling Method:   Non-Probability Sample
Study Population

60 from each groups. Healthy subjects - recruited from voluntary basis. LRTI - recruited from patient wards with consent. URTI - recruited from out-patient clinic with consent.

Criteria

Inclusion Criteria:

  1. Adult patients (>18 years old) that can give valid consent
  2. URTI: with symptoms such as coryza, sore throat, nasal discharge, cough and sputum +/- fever. Amongst these, cough should be a major complaint.
  3. LRTI (CAP): acute lower respiratory illness of no other known cause which is usually associated with fever, symptoms and signs of the chest and abnormalities on the CXR. (BTS 1993).

Exclusion Criteria:

  1. Pneumonia developed at or after 48 hours, or history of hospital admissions within 1 month of the present admission (to exclude hospital-acquired infections)
  2. Patients who are unable to cooperate with the study protocols (such as mentally confused, dementia) or are physically unable to sit or stand independently to carry out the tests optimally.
  3. Patients with TOCC associations with infections such Avian Flu or SARS (travel to endemic areas, at-risk occupations, close contacts with index cases, especially with compatible clinical features) or NPA revealed positivity of influenza A/B
  4. Patients who are clinically or haemodynamically unstable, such as the need for inotropes, oxygen supplement of >2L/min, any types of shock, etc.
  5. Underlying diseases that might affect the coughing effort (such as musculoskeletal diseases, or severe kyphoscoliosis)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00517660

Locations
China
Queen Elizabeth Hospital
Hong Kong, China
Sponsors and Collaborators
Hospital Authority, Hong Kong
Hong Kong University of Science and Technology
Investigators
Principal Investigator: Ming Fang, Prof Institute for the Environment, The Hong Kong University of Science and Technology
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00517660     History of Changes
Other Study ID Numbers: KC/KE-04-0071/ER-1, HARECCTR0500055
Study First Received: August 15, 2007
Last Updated: August 21, 2013
Health Authority: Hong Kong: Ethics Committee

Keywords provided by Hospital Authority, Hong Kong:
Healthy subjects
Lower Respiratory Tract Infections
Upper Respiratory Tract Infections

Additional relevant MeSH terms:
Respiratory Tract Infections
Infection
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on August 28, 2014